BCL2 and acute myeloid leukemia: Recently, the B-cell lymphoma 2 (BCL-2) protein has emerged as an exciting therapeutic target that has shown clinical benefits in adult patients with AML, both in the upfront and relapsed/refractory (r/r) setting [9,10,11].